#1 Clinical Trials Search in Europe

Tedizolid Phosphate

Tedizolid phosphate is an antibiotic medication being studied in clinical trials for treating various bacterial infections. These trials are evaluating its safety, effectiveness, and optimal dosing across different patient populations, including adults, children, and those with specific conditions like skin infections or prosthetic joint infections. The studies are examining both oral and intravenous formulations of tedizolid phosphate to determine how it performs compared to other antibiotics and in different patient scenarios.

Table of Contents

What is Tedizolid Phosphate?

Tedizolid phosphate is an antibiotic medication used to treat certain bacterial infections. It’s also known by several other names, including Sivextro, TR-701 FA, and MK-1986[1][2]. This drug belongs to a class of antibiotics called oxazolidinones, which work by stopping the growth of bacteria[3].

What Conditions Does It Treat?

Tedizolid phosphate is primarily used to treat infections caused by Gram-positive bacteria, which are a specific type of bacteria. It’s particularly effective against certain types of antibiotic-resistant bacteria. The main conditions it treats include:

  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI): These are serious skin infections that can involve deeper layers of skin and surrounding tissues[4].
  • Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections: MRSA is a type of bacteria that’s resistant to many common antibiotics[5].
  • Nosocomial Pneumonia: This is a type of pneumonia (lung infection) that patients can develop while in a hospital[6].

How is It Administered?

Tedizolid phosphate can be given in two main ways:

  1. Intravenous (IV) Infusion: This means the drug is given directly into a vein through a needle or catheter[1].
  2. Oral Tablet or Suspension: The drug can also be taken by mouth as a tablet or liquid suspension[2].

The typical dose for adults is 200 mg once daily, usually for 6 to 14 days, depending on the type and severity of the infection[5]. For children and infants, the dose is based on their weight[4].

Effectiveness

Studies have shown that tedizolid phosphate is effective in treating various bacterial infections. In clinical trials, it has been compared to other antibiotics like linezolid and has shown similar or better effectiveness[6]. For skin infections, researchers have observed significant reductions in the size of infected areas after treatment with tedizolid phosphate[5].

Safety and Side Effects

Like all medications, tedizolid phosphate can cause side effects. Common side effects may include:

  • Nausea
  • Headache
  • Diarrhea
  • Vomiting
  • Dizziness

More serious side effects, though less common, can include:

  • Bone marrow toxicity: This can affect blood cell production[3].
  • Peripheral neuropathy: This is damage to the nerves outside the brain and spinal cord, which can cause numbness or tingling[3].
  • Optic nerve damage: In rare cases, this could affect vision[3].

It’s important to report any side effects to your healthcare provider. They will monitor your health closely while you’re taking this medication[7].

Special Populations

Research is ongoing to understand how tedizolid phosphate works in different groups of people:

  • Children and Infants: Studies are being conducted to determine safe and effective dosing for children of different ages, including newborns[8].
  • Obese Patients: Research has looked at how the drug is processed in the bodies of people with obesity compared to those without[1].
  • Patients with Prosthetic Joint Infections: Some studies are exploring the use of tedizolid phosphate for long-term treatment of infections in artificial joints[3].

Ongoing Research

Scientists continue to study tedizolid phosphate to learn more about its uses and effects. Current areas of research include:

  • Its effectiveness against different types of bacteria[6].
  • How it interacts with other medications[7].
  • Developing new forms of the medication, such as different types of oral suspensions[9].
  • Its potential use in treating more severe or long-lasting infections[3].

As research continues, we may learn about new uses for tedizolid phosphate or better ways to use it to treat infections.

Aspect Details
Study Populations Adults, children (birth to <12 years), obese and non-obese patients
Infections Studied Skin infections, pneumonia, prosthetic joint infections, gram-positive bacterial infections
Administration Routes Oral (tablets, suspensions) and intravenous (IV)
Comparator Drugs Linezolid, vancomycin, clindamycin, among others
Key Outcomes Measured Pharmacokinetics, safety (adverse events), efficacy (clinical response, mortality)
Special Considerations Dosing in obese patients, long-term safety, use in pediatric populations
Formulation Studies Comparing different oral formulations for bioequivalence

FAQ

  • What types of infections is tedizolid phosphate being studied for? Tedizolid phosphate is being studied for various bacterial infections, including acute bacterial skin and skin structure infections (ABSSSI), gram-positive infections, nosocomial pneumonia, and prosthetic joint infections. It's being evaluated in both adults and children for these conditions.
  • How is tedizolid phosphate administered in these trials? Tedizolid phosphate is being studied in both oral and intravenous (IV) formulations. Some trials are examining oral tablets or suspensions, while others are looking at IV infusions. The specific administration method often depends on the patient population and type of infection being treated.
  • What age groups are being included in tedizolid phosphate trials? The trials are including a wide range of age groups, from newborns to adults. Some studies focus specifically on pediatric populations, including premature infants, full-term newborns, and children up to 12 years old. Other trials are conducted with adult participants.
  • How does tedizolid phosphate compare to other antibiotics? Several trials are comparing tedizolid phosphate to other antibiotics like linezolid, vancomycin, and clindamycin. These studies aim to determine if tedizolid phosphate is as effective or potentially superior in treating certain infections, while also comparing their safety profiles.
  • What are the main outcomes being measured in these trials? The main outcomes being measured include pharmacokinetics (how the drug moves through the body), safety (adverse events and tolerability), and efficacy (clinical response and cure rates). Some trials are also looking at specific aspects like the drug's effects on certain enzymes or its performance in obese versus non-obese patients.

Ongoing Clinical Trials on Tedizolid Phosphate

  • Study on the Effects of Tedizolid and Linezolid for Patients with Suspected Lung Tuberculosis

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A type of bacterial infection affecting the skin and underlying tissues, often requiring antibiotic treatment.
  • Nosocomial Pneumonia: A lung infection that develops during a hospital stay, often in patients on ventilators (also called hospital-acquired pneumonia).
  • Prosthetic Joint Infection: An infection that occurs around an artificial joint implant, such as a hip or knee replacement.
  • Bioequivalence: A comparison of different drug formulations to determine if they have the same biological effects and availability in the body.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Intent-to-Treat (ITT) Population: All participants who are randomized into a clinical trial, regardless of whether they actually received the treatment or completed the study.
  • Clinical Response: The measurement of how well a patient's symptoms or condition improves in response to a treatment.
  • Gram-Positive Bacteria: A class of bacteria that retain crystal violet dye in a laboratory staining procedure, often including species that can cause serious infections.
  • Methicillin-Resistant Staphylococcus Aureus (MRSA): A type of bacteria resistant to certain antibiotics, making infections harder to treat.

References

  1. https://clinicaltrials.gov/study/NCT02342418
  2. https://clinicaltrials.gov/study/NCT02750761
  3. https://clinicaltrials.gov/study/NCT03378427
  4. https://clinicaltrials.gov/study/NCT03176134
  5. https://clinicaltrials.gov/study/NCT01967225
  6. https://clinicaltrials.gov/study/NCT02019420
  7. https://clinicaltrials.gov/study/NCT02477514
  8. https://clinicaltrials.gov/study/NCT03217565
  9. https://clinicaltrials.gov/study/NCT06609161